Literature DB >> 8562942

High incidence of potential p53 inactivation in poor outcome childhood acute lymphoblastic leukemia at diagnosis.

D I Marks1, B W Kurz, M P Link, E Ng, J J Shuster, S J Lauer, I Brodsky, D S Haines.   

Abstract

Previous studies have indicated that p53 gene mutations were an uncommon event in acute lymphoblastic leukemia (ALL) in children. In one series of 330 patients, p53 mutations were seen in fewer than 3%. We analyzed bone marrow mononuclear cells derived from 10 children with ALL at diagnosis who subsequently failed to achieve a complete remission or who developed relapse within 6 months of attaining complete remission for p53 gene mutations and mdm-2 overexpression. We found that three children had p53 gene mutations, and four overexpressed mdm-2. Also, experiments comparing relative levels of mdm-2 RNA and protein in these patients demonstrated that mdm-2 overexpression can occur at the transcriptional and posttranscriptional level in primary leukemic cells. Although we were unable to link Waf-1 RNA expression with p53 status in childhood ALL, our data show potential p53 inactivation by multiple mechanisms in a large percentage of these patients and demonstrate that these alterations can be detected at diagnosis. Inactivation of the p53 pathway may, therefore, be important in children with ALL who fail to respond to treatment and may be useful for the early identification of children requiring alternative therapies.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8562942

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  15 in total

1.  Comparison of mutant and wild-type p53 proteins in Merkel cell carcinoma.

Authors:  H J Carson; N E Lueck; B C Horten
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

2.  Apoptosis in haematological malignancies.

Authors:  J A DiGiuseppe; M B Kastan
Journal:  J Clin Pathol       Date:  1997-05       Impact factor: 3.411

3.  Triptolide inhibits MDM2 and induces apoptosis in acute lymphoblastic leukemia cells through a p53-independent pathway.

Authors:  Mei Huang; Hailong Zhang; Tao Liu; Dan Tian; Lubing Gu; Muxiang Zhou
Journal:  Mol Cancer Ther       Date:  2012-12-12       Impact factor: 6.261

4.  Regulation of Mdm2 protein stability and the p53 response by NEDD4-1 E3 ligase.

Authors:  C Xu; C D Fan; X Wang
Journal:  Oncogene       Date:  2014-01-13       Impact factor: 9.867

5.  Regulation of the Mdm2-p53 pathway by the ubiquitin E3 ligase MARCH7.

Authors:  Kailiang Zhao; Yang Yang; Guang Zhang; Chenfeng Wang; Decai Wang; Mian Wu; Yide Mei
Journal:  EMBO Rep       Date:  2018-01-02       Impact factor: 8.807

6.  Inhibition of MDM2 by a Rhein-Derived Compound AQ-101 Suppresses Cancer Development in SCID Mice.

Authors:  Lubing Gu; Hailong Zhang; Tao Liu; Alexander Draganov; Sha Yi; Binghe Wang; Muxiang Zhou
Journal:  Mol Cancer Ther       Date:  2017-12-27       Impact factor: 6.261

7.  p53-independent epigenetic repression of the p21(WAF1) gene in T-cell acute lymphoblastic leukemia.

Authors:  Carwyn Davies; Linda A Hogarth; Philipp A Dietrich; Petra S Bachmann; Karen L Mackenzie; Andrew G Hall; Richard B Lock
Journal:  J Biol Chem       Date:  2011-09-07       Impact factor: 5.157

8.  The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia.

Authors:  Philip Saunders; Adam Cisterne; Jocelyn Weiss; Kenneth F Bradstock; Linda J Bendall
Journal:  Haematologica       Date:  2010-10-15       Impact factor: 9.941

9.  MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2.

Authors:  L Gu; N Zhu; H W Findley; M Zhou
Journal:  Leukemia       Date:  2008-02-14       Impact factor: 11.528

10.  p21(WAF1) modulates drug-induced apoptosis and cell cycle arrest in B-cell precursor acute lymphoblastic leukemia.

Authors:  Carwyn Davies; Linda A Hogarth; Karen L Mackenzie; Andrew G Hall; Richard B Lock
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.